Status:
UNKNOWN
FLT3-ITD Gene Mutation and CD135 Expression in Acute Myeloid Leukemia.
Lead Sponsor:
Assiut University
Conditions:
Acute Myeloid Leukemia
Eligibility:
All Genders
Brief Summary
1. To evaluate expression levels of CD135 2. To assess the frequency of FLT3 gene mutations (ITD) 3. association between FLT3-ITD mutation and CD135 expression and their correlation with hematological...
Detailed Description
Acute leukemias are clonal malignant diseases of immature hematopoietic system ,characterized by clonal evolution and considerable genetic, epigenetic, and phenotypic heterogeneity,and constitute a co...
Eligibility Criteria
Inclusion
- Newly diagnosed Patients with acute myeloid leukemia (AML), who fullfill the WHO criteria.
Exclusion
- AML on top of myeloproliferative neoplasms or MDS.
- previously diagnosed AML on treatment
- Patients with any other type of malignant tumors
Key Trial Info
Start Date :
June 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 1 2024
Estimated Enrollment :
82 Patients enrolled
Trial Details
Trial ID
NCT05383014
Start Date
June 1 2022
End Date
July 1 2024
Last Update
May 19 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.